» Articles » PMID: 15967333

Silent Versus Cranial Giant Cell Arteritis. Initial Presentation and Outcome of 50 Biopsy-proven Cases

Overview
Specialty General Medicine
Date 2005 Jun 22
PMID 15967333
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND: The objective of the present study was to compare the silent form of giant cell arteritis (GCA) to the classic cephalic form of the disease. METHODS: We conducted a retrospective study based on a chart review of 50 consecutive, biopsy-proven GCA, recorded at a department of internal medicine. We sought to distinguish a silent form, defined by a prolonged inflammatory syndrome or fever of unknown origin with the absence of cephalic signs, polymyalgia rheumatica, or large artery involvement, from an overt "classic" cranial temporal arteritis. RESULTS: The prevalence of the silent form of GCA was 46% in our study. Abnormal temporal arteries were more frequent in the cephalic group. The silent GCA group had higher C-reactive protein levels (p<0.05), a higher platelet count (p<0.05), and lower serum albumin (p<0.05). There was no significant difference in temporal artery specimens in the two groups. Clinical relapses tended to be more frequent, and patients free of corticosteroids tended to be less frequent, in the cephalic group, though the difference was not statistically significant. CONCLUSIONS: The silent and cephalic forms of GCA could have distinct clinical and biological patterns and different outcomes. The limitation of our study was its retrospective design. Further studies are required to determine if this distinction is useful in treating GCA patients.

Citing Articles

Headache-Related Characteristics of Biopsy-Confirmed Giant Cell Arteritis and the Relationship of Transmural Inflammation With Artery Tenderness and Chordal Thickening.

Shimohama S, Imai N, Tsubata T, Shinohara K, Moriya A, Yagi N Cureus. 2024; 16(3):e56843.

PMID: 38659551 PMC: 11039303. DOI: 10.7759/cureus.56843.


Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis....

Sanchez-Alvarez C, Bond M, Soowamber M, Camellino D, Anderson M, Langford C RMD Open. 2023; 9(2).

PMID: 37349123 PMC: 10314653. DOI: 10.1136/rmdopen-2023-003233.


Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes.

Wiberg F, Naderi N, Mohammad A, Turesson C Rheumatology (Oxford). 2021; 61(1):383-387.

PMID: 33871583 PMC: 8742823. DOI: 10.1093/rheumatology/keab353.


Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Monti S, Agueda A, Luqmani R, Buttgereit F, Cid M, Dejaco C RMD Open. 2019; 5(2):e001003.

PMID: 31673411 PMC: 6803016. DOI: 10.1136/rmdopen-2019-001003.


Differences in clinical manifestations and prognosis of Chinese giant cell arteritis patients with or without polymyalgia rheumatica.

Zhang Y, Wang D, Chu X, Zhang W, Zeng X Ir J Med Sci. 2018; 188(2):713-720.

PMID: 30251177 DOI: 10.1007/s11845-018-1903-1.